Pasithea Therapeutics KTTA Insider Ownership

NASDAQ KTTA

$0.49 +0.08 (+18.98%)

At close: Oct 21, 2026 · 4:00 PM EDT

Insider Holdings by Owner

4.31Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

12.59%

■0% pp QoQ

Shares Held by Insiders

4.21Mn

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

33.41Mn

33,414,448 shares

Direct Holdings

372.36K

Indirect: 3.84Mn

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Pasithea Therapeutics insiders were all purchases, totaling $178,000 (266.67K shares).

Pasithea Therapeutics' open-market purchases in the past 12 months came from 3 insiders; no insider sold.
Among Pasithea Therapeutics insiders, Lawrence Steinman (Director) led open-market buying over the past 12 months with $100,000 of purchases (133.33K shares); the latest was on November 28, 2025.
The latest open-market trade in KTTA stock by an insider was a purchase of 100K shares for $53,000 by Coastlands Capital LP (10% owner) on June 17, 2026.
Apart from open-market trades, KTTA insiders received 60K shares in stock awards in the past 12 months.
Per Business Quant data, Pasithea Therapeutics insiders hold 4.21Mn shares in total based on their latest Form 4 filings, unchanged from 4.21Mn shares at the end of Q2 2026.
Pasithea Therapeutics insiders hold 372.36K shares directly (8.85% of their total) and 3.84Mn shares (91.15%) indirectly, through entities such as trusts and partnerships.
Per Business Quant, 7 insiders of KTTA hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
Pasithea Therapeutics' three largest insider shareholders, based on their latest Form 4 filings, are Coastlands Capital LP (10% owner, 3.84Mn shares), Lawrence Steinman (Director, 199.69K shares) and Tiago Marques (Chief Executive Officer, 73.33K shares).
The largest insider, Coastlands Capital LP, holds 91.15% of KTTA's insider total.
Institutions held 50.24% of Pasithea Therapeutics' outstanding shares in their Q2 2026 13F filings, insiders about 12.59% based on their latest Form 4 filings, and other investors, including the public, the remaining 37.17%.
In the last 12 months, 19 Form 4 filings with transactions in KTTA stock came from 8 insiders.
This summary of Pasithea Therapeutics insider activity covers Form 4 filings through June 22, 2026.

Form 4 Holdings

Insiders Holding KTTA

Insiders 10

Shares held 4.31Mn

Of outstanding 12.90%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Capital Lp Coastlands	TenPercentOwner	0	3,835,035	3,835,035	89.0%	22 Jun, 2026
2	Lawrence Steinman	Director	199,691	0	199,691	4.6%	01 Dec, 2025
3	Eric Shahinian	Other	0	89,421	89,421	2.1%	30 Sep, 2022
4	Tiago Marques	Chief Executive Officer	73,334	0	73,334	1.7%	01 Dec, 2025
5	Simon Dumesnil	Director	35,833	0	35,833	0.8%	01 Dec, 2025
6	Emer Leahy	Director	33,333	0	33,333	0.8%	01 Dec, 2025
7	Daniel H Schneiderman	Chief Financial Officer	26,667	0	26,667	0.6%	01 Dec, 2025
8	David Delaney	Other	0	11,376	11,376	0.3%	19 Oct, 2022
9	Alfred J Novak	Director	3,500	0	3,500	0.1%	14 Jun, 2024
10	Avi Geller	Other	0	2,732	2,732	0.1%	26 Aug, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

79 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
17 Jun, 2026	Capital Lp Coastlands	TenPercentOwner	Acquired P	100,000	$0.53	$53.00K	3,835,035	Indirect
01 May, 2026	Simon Dumesnil	Director	Acquired A	152,783	$0.00	$0	152,783	Direct
01 May, 2026	Kartik Krishnan	Chief Medical Officer	Acquired A	1,129,323	$0.00	$0	1,129,323	Direct
01 May, 2026	Daniel H Schneiderman	Chief Financial Officer	Acquired A	1,129,323	$0.00	$0	1,129,323	Direct
01 May, 2026	Alfred J Novak	Director	Acquired A	152,783	$0.00	$0	152,783	Direct
01 May, 2026	Lawrence Steinman	Director	Acquired A	152,783	$0.00	$0	152,783	Direct
01 May, 2026	Tiago Marques	Chief Executive Officer	Acquired A	1,756,069	$0.00	$0	1,756,069	Direct
01 May, 2026	Emer Leahy	Director	Acquired A	152,783	$0.00	$0	152,783	Direct
28 Nov, 2025	Lawrence Steinman	Director	Acquired P	133,333	$0.75	$100.00K	199,691	Direct
28 Nov, 2025	Simon Dumesnil	Director	Acquired P	33,333	$0.75	$25.00K	35,833	Direct
28 Nov, 2025	Tiago Marques	Chief Executive Officer	Acquired P	33,333	$0.75	$25.00K	73,334	Direct
28 Nov, 2025	Emer Leahy	Director	Acquired A	33,333	$0.75	$25.00K	33,333	Direct
28 Nov, 2025	Daniel H Schneiderman	Chief Financial Officer	Acquired A	26,667	$0.75	$20.00K	26,667	Direct
24 Oct, 2025	Daniel H Schneiderman	Chief Financial Officer	Acquired A	317,266	$0.00	$0	317,266	Direct
24 Oct, 2025	Lawrence Steinman	Director	Acquired A	242,913	$0.00	$0	242,913	Direct
24 Oct, 2025	Simon Dumesnil	Director	Acquired A	42,913	$0.00	$0	42,913	Direct
24 Oct, 2025	Tiago Marques	Chief Executive Officer	Acquired A	493,341	$0.00	$0	493,341	Direct
24 Oct, 2025	Emer Leahy	Director	Acquired A	42,913	$0.00	$0	42,913	Direct
24 Oct, 2025	Alfred J Novak	Director	Acquired A	42,913	$0.00	$0	42,913	Direct
12 May, 2025	Tiago Marques	Chief Executive Officer	Disposed S	960	$0.83	$792	40,001	Direct

Showing 1 to 20 of 79 transactions